Shen Yuanyuan, Pi Zhaoke, Yan Fei, Yeh Chih-Kuang, Zeng Xiaojun, Diao Xianfen, Hu Yaxin, Chen Siping, Chen Xin, Zheng Hairong
National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, People's Republic of China.
Paul C Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, People's Republic of China.
Int J Nanomedicine. 2017 Aug 9;12:5613-5629. doi: 10.2147/IJN.S136401. eCollection 2017.
Paclitaxel liposomes (PTX-LIPO) are a clinically promising antineoplastic drug formulation for the treatment of various extracranial cancers, excluding glioblastoma. A main reason for this is the presence of the blood-brain barrier (BBB) or blood-tumor barrier (BTB), preventing liposomal drugs from crossing at a therapeutically meaningful level. Focused ultrasound (FUS) in conjunction with microbubbles (MBs) has been suggested in many studies to be an effective approach to increase the BBB or BTB permeability. In this study, we investigated the feasibility of enhancing the delivery of PTX-LIPO in intracranial glioblastoma-bearing nude mice using pulsed low-intensity FUS exposure in the presence of MBs. Our results showed that the delivery efficiency of PTX-LIPO could be effectively improved in terms of the penetration of both the BBB in vitro and BTB in vivo by pulsed FUS sonication with a 10 ms pulse length and 1 Hz pulse repetition frequency at 0.64 MPa peak-rarefactional pressure in the presence of MBs. Quantitative analysis showed that a 2-fold higher drug concentration had accumulated in the glioblastoma 3 h after FUS treatment, with 7.20±1.18 µg PTX per g glioma tissue. Longitudinal magnetic resonance imaging analysis illustrated that the intracranial glioblastoma progression in nude mice treated with PTX-LIPO delivered via FUS with MBs was suppressed consistently for 4 weeks compared to the untreated group. The medium survival time of these tumor-bearing nude mice was significantly prolonged by 20.8%, compared to the untreated nude mice. Immunohistochemical analysis further confirmed the antiproliferation effect and cell apoptosis induction. Our study demonstrated that noninvasive low-intensity FUS with MBs can be used as an effective approach to deliver PTX-LIPO in order to improve their chemotherapy efficacy toward glioblastoma.
紫杉醇脂质体(PTX-LIPO)是一种在临床上有前景的抗肿瘤药物制剂,可用于治疗除胶质母细胞瘤外的各种颅外癌症。主要原因是存在血脑屏障(BBB)或血肿瘤屏障(BTB),阻止脂质体药物以具有治疗意义的水平穿过。许多研究表明,聚焦超声(FUS)联合微泡(MBs)是增加血脑屏障或血肿瘤屏障通透性的有效方法。在本研究中,我们研究了在存在微泡的情况下,使用脉冲低强度FUS照射增强PTX-LIPO在颅内荷胶质母细胞瘤裸鼠中的递送的可行性。我们的结果表明,在存在微泡的情况下,通过在0.64 MPa峰值-稀疏压力下以10 ms脉冲长度和1 Hz脉冲重复频率进行脉冲FUS超声处理,PTX-LIPO的递送效率在体外血脑屏障和体内血肿瘤屏障的穿透方面都能得到有效提高。定量分析表明,FUS治疗后3小时,胶质母细胞瘤中积累的药物浓度高出2倍,每克胶质瘤组织中含有7.20±1.18 μg紫杉醇。纵向磁共振成像分析表明,与未治疗组相比,通过FUS联合微泡递送PTX-LIPO治疗的裸鼠颅内胶质母细胞瘤进展持续被抑制4周。这些荷瘤裸鼠的中位生存时间比未治疗的裸鼠显著延长了20.8%。免疫组织化学分析进一步证实了其抗增殖作用和诱导细胞凋亡。我们的研究表明,无创低强度FUS联合微泡可作为一种有效的方法来递送PTX-LIPO,以提高其对胶质母细胞瘤的化疗疗效。